Bayer (BAYN.DE) stock price, revenue, and financials

Bayer annual revenue was €35.02 b in FY 2017

€35 B

Bayer Revenue FY, 2017
Bayer Revenue growth (FY, 2016 - FY, 2017), %(25%)
Bayer Gross profit (FY, 2017)23.6 B
Bayer Gross profit margin (FY, 2017), %67.5%
Bayer Net income (FY, 2017)8.1 B
Bayer EBIT (FY, 2017)5.9 B
Bayer Cash, 31-Dec-20177.6 B
Bayer EV104.2 B

Bayer Revenue

Bayer revenue was €35.02 b in FY, 2017 which is a 25.1% year over year decrease from the previous period.

Embed Graph

Bayer Revenue Breakdown

Embed Graph

Bayer revenue breakdown by business segment: 27.4% from CropScience , 48.1% from Pharmaceuticals, 16.7% from Consumer Health and 7.8% from Other

Bayer revenue breakdown by geographic segment: 38.2% from Europe / Middle East / Africa, 29.0% from North America, 21.8% from Asia / Pacific and 11.0% from Latin America

Bayer Income Statement

Annual

EURFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

40.2b41.3b46.3b46.8b35.0b

Revenue growth, %

3%12%1%(25%)

Cost of goods sold

19.5b19.9b21.2b20.3b11.4b

Gross profit

20.6b21.4b25.2b26.5b23.6b

Gross profit Margin, %

51%52%54%57%67%

Sales and marketing expense

10.3b10.7b12.4b12.5b11.1b

R&D expense

3.4b3.5b4.3b4.7b4.5b

General and administrative expense

1.7b1.7b2.1b2.3b2.0b

Operating expense total

15.4b15.9b18.7b19.4b17.7b

EBIT

5.9b

EBIT margin, %

17%

Interest expense

1.1b1.3b1.4b1.3b1.6b

Interest income

389.0m343.0m371.0m151.0m289.0m

Pre tax profit

4.2b4.4b5.2b5.9b4.6b

Income tax expense

1.0b1.1b1.2b1.3b1.3b

Net Income

3.2b3.4b4.1b4.5b8.1b

Quarterly

EURQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

11.9b11.8b8.3b13.2b12.2b8.0b

Cost of goods sold

5.0b5.0b2.7b5.3b5.1b2.6b

Gross profit

6.8b6.8b5.5b7.9b7.1b5.5b

Gross profit Margin, %

57%58%67%60%58%68%

Sales and marketing expense

2.9b3.1b2.6b3.0b3.2b2.5b

R&D expense

1.1b1.1b1.1b1.2b1.2b1.1b

General and administrative expense

495.0m489.0m483.0m572.0m608.0m485.0m

Operating expense total

4.5b4.7b4.2b4.7b4.9b4.1b

Interest expense

347.0m350.0m265.0m371.0m495.0m479.0m

Interest income

37.0m42.0m33.0m35.0m101.0m84.0m

Pre tax profit

2.0b1.8b1.2b2.8b1.7b985.0m

Income tax expense

474.0m431.0m207.0m595.0m417.0m212.0m

Net Income

1.6b1.4b1.3b2.3b1.5b4.2b

Bayer Balance Sheet

Annual

EURFY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.9b1.9b1.9b7.6b

Accounts Receivable

9.1b9.9b11.0b8.6b

Inventories

8.5b8.6b8.4b6.6b

Current Assets

22.2b23.8b30.4b30.1b

PP&E

11.4b12.4b13.1b7.6b

Goodwill

16.2b16.1b16.3b14.8b

Total Assets

70.2b73.9b82.2b75.1b

Accounts Payable

5.4b5.9b6.4b5.1b

Short-term debt

1.9b

Current Liabilities

15.5b17.0b18.5b13.6b

Long-term debt

12.5b

Non-Current Liabilities

34.5b31.5b31.8b24.6b

Total Debt

14.4b

Common Stock

2.1b2.1b2.1b2.1b

Retained Earnings

26.9b

Total Equity

20.2b25.4b31.9b36.9b

Debt to Equity Ratio

0.4 x

Debt to Assets Ratio

0.2 x

Financial Leverage

3.5 x2.9 x2.6 x2 x

Quarterly

EURQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

3.6b1.1b1.2b2.2b2.8b5.6b

Accounts Receivable

11.6b2.1b10.8b13.0b1.7b8.8b

Inventories

8.5b8.3b8.4b8.7b8.5b6.7b

Current Assets

26.7b24.7b25.2b33.4b32.7b30.8b

PP&E

12.1b12.3b12.4b13.1b12.7b7.4b

Goodwill

15.8b16.0b15.9b16.3b15.8b14.9b

Total Assets

76.6b75.5b76.5b85.1b82.6b76.7b

Accounts Payable

5.0b5.1b4.9b5.7b5.2b3.9b

Current Liabilities

17.4b17.1b16.7b19.6b18.8b14.9b

Non-Current Liabilities

34.4b34.4b35.1b29.6b28.4b24.5b

Common Stock

2.1b2.1b2.1b2.1b2.1b2.1b

Total Equity

24.8b24.0b24.8b35.9b35.5b37.3b

Financial Leverage

3.1 x3.1 x3.1 x2.4 x2.3 x2.1 x

Bayer Cash Flow

Annual

EURFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

3.3b4.0b4.6b

Depreciation and Amortization

2.9b3.3b3.7b2.7b

Accounts Receivable

(1.1b)(1.1b)(552.0m)(18.0m)

Inventories

(748.0m)(191.0m)(3.0m)(293.0m)

Accounts Payable

485.0m400.0m452.0m265.0m

Cash From Operating Activities

5.7b6.9b9.1b8.1b

Purchases of PP&E

(2.4b)(2.5b)(2.6b)(2.4b)

Cash From Investing Activities

(15.5b)(2.8b)(8.7b)(432.0m)

Long-term Borrowings

(15.7b)(19.5b)(15.9b)(12.8b)

Dividends Paid

(1.7b)(1.9b)(2.1b)(2.4b)

Cash From Financing Activities

9.7b(4.0b)(350.0m)(1.9b)

Net Change in Cash

7.0m154.0m10.0m5.8b

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

1.5b1.4b957.0m2.2b1.3b773.0m

Depreciation and Amortization

1.0b814.0m599.0m730.0m832.0m581.0m

Accounts Receivable

(1.7b)170.0m884.0m(2.0b)280.0m1.3b

Inventories

(119.0m)190.0m(80.0m)(257.0m)(12.0m)(314.0m)

Accounts Payable

(893.0m)39.0m(178.0m)(694.0m)(290.0m)(25.0m)

Cash From Operating Activities

1.3b2.0b3.1b841.0m2.3b2.7b

Purchases of PP&E

(363.0m)(589.0m)(656.0m)(415.0m)(476.0m)(557.0m)

Cash From Investing Activities

(462.0m)(1.2b)(2.0b)(1.1b)(1.2b)179.0m

Long-term Borrowings

(3.4b)(4.3b)(5.0b)(1.0b)(410.0m)(4.4b)

Dividends Paid

(2.1b)(2.0m)(2.4b)(3.0m)

Cash From Financing Activities

823.0m(3.2b)(846.0m)611.0m(549.0m)(37.0m)

Net Change in Cash

1.7b(2.5b)168.0m316.0m586.0m2.8b

Bayer Ratios

EURY, 2017

EV/EBIT

17.7 x

EV/CFO

12.8 x

Revenue/Employee

350.8k

Debt/Equity

0.4 x

Debt/Assets

0.2 x

Financial Leverage

2 x

Bayer Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Countries

147 151 152

Suppliers

112 k112.50 k110.90 k

Water Consumption, Mcm

361 450 346 330

Engineers And Scientists

15 k

Patent Applications

68.20 k66.70 k50.80 k

Patents Issued

8.30 k7.20 k5 k

Projects Supported

53 50

Phase III Trials Products

14 17 17